Posttest- Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management Evaluation (ID: i757)
Georgia AFP
Friday, November 13, 2020

Question Title

* 1. Following your participation in this activity, how confident are you in the management of patients with obesity in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. Jessica, who is 32 and has a BMI of 36, is consulting her primary care physician for a non-weight related problem. Seeing that Jessica’s blood pressure is at an unhealthy level and her blood glucose has entered the prediabetes category, the doctor would like to talk with Jessica about weight intervention options. What should she do first?

Ask Jessica for permission to discuss her weight

Acknowledge Jessica’s age, height, weight, and BMI

Access Jessica’s medical history to see if there has been recent weight loss/weight gain

Accept that Jessica, like most patients, will likely be unwilling to address her weight

Question Title

* 3. Which of the following areas are most heavily affected by obesity prevalence and why, according to a CDC analysis that divided the United States into 9 regional divisions?

Metropolitan areas because traffic limits mobility on foot and highly priced indoor recreational opportunities limit participation

Urban areas, because they are more heavily affected by crime, which inhibits outdoor exercise

Suburban areas, because they lack adequate public transportation and businesses are spread far apart, forcing residents to drive where they need to go

Rural areas, because they lack wide availability of fresh food, paved walkways, and areas for indoor and outdoor recreation

Question Title

* 4. Mrs. Wong, a 35-year-old Asian woman, consults her nurse practitioner about feeling “sluggish,” tired, and uncomfortable most of the time. Additionally, her blood pressure is slightly elevated. Mrs. Wong’s BMI is 28. What should the nurse practitioner tell Mrs. Wong about obesity being a possible cause for her complaints?

Nothing; because Mrs. Wong’s BMI is under 30, she doesn’t have obesity

Mrs. Wong should be informed only that according to the BMI chart, she is overweight

It isn’t necessary to broach this subject because people with Asian ancestry have low obesity prevalence rates

Miss Wong should be advised that she has obesity due to the fact that obesity BMI for Asian Americans starts at 27.5

Question Title

* 5. Dr. Smith, a primary care physician, is considering using the AHA/ACC/TOS guideline algorithm with one of his patients who has a BMI of 27 with weight-related comorbidities. Would this this algorithm be an appropriate tool?

No, because the patient does not have a BMI ≥30

Yes, because this is a BMI-centric guideline for patients with BMI ≥25 and CVD risk factors

No, because this guideline does not sufficiently emphasize behavioral and lifestyle interventions

Yes, but it should be used only in tandem with the complication-centric AACE guideline algorithm

Question Title

* 6. Which patients should be considered for antiobesity medication? According to AACE guidelines, appropriate anti-obesity medication candidates are patients who have:

A BMI ≥30 who have been unsuccessful with ≥6 months of lifestyle interventions

Shown a repeated weight loss and regain pattern (≥2 times) within the previous year

Successfully lost ≥10% of their body weight but need additional help to get to goal weight

A BMI ≥30 with no weight-related complications or with a BMI ≥27 and ≥1 weight-related complication

Question Title

* 7. Phase 3 preliminary trial results showing an average weight loss >18% after 68 weeks, were recently released for which agent now in clinical development?

Dapagliflozin, an SGLT2 inhibitor

Semaglutide, a GLP-1 receptor agonist

Tirzepatide, a GIP-GLP-1 dual inhibitor

Setmelanotide, an MC4R activator

Question Title

* 8. Which FDA-approved antiobesity medication or combination should be avoided in patients with seizure disorders, based on safety profile and contraindications?

Liraglutide

Phentermine

Naltrexone/bupropion

Phentermine/topiramate

Question Title

* 9. What is your degree?

MD/DO

Other (please specify)

Question Title

* 10. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 11. How many patients with obesity do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 12. Please select the option that best describes your practice setting:

Academic medical center

Community hospital or medical center

VA, DOD or other government

Managed Care

Research

Pharmaceutical industry

Question Title

* 13. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 14. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 15. Which new strategies/skills/information will you incorporate into your practice? Please select all that apply.

Recognition of regional discrepancies and disparities in obesity prevalence

Using the 5 A’s as a dialogue and partnership tool to facilitate weight management

Strategies for motivating and encouraging incremental weight loss for improved cardiovascular health

Recommendations from BMI-centric and complication-centric clinical guidelines

Knowledge regarding the mechanisms of action of currently available anti-obesity medications

Selecting anti-obesity pharmacotherapies that correspond to each patient’s comorbidities and characteristics

Information about clinical trial efficacy and safety findings for anti-obesity treatments in late-phase development

Question Title

* 16. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 17. After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion	Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion Strongly agree	Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion Agree	Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion Neutral	Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion Disagree	Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion Strongly disagree
Examine regional and ethnic disparities to tailor obesity interventions appropriately	Examine regional and ethnic disparities to tailor obesity interventions appropriately Strongly agree	Examine regional and ethnic disparities to tailor obesity interventions appropriately Agree	Examine regional and ethnic disparities to tailor obesity interventions appropriately Neutral	Examine regional and ethnic disparities to tailor obesity interventions appropriately Disagree	Examine regional and ethnic disparities to tailor obesity interventions appropriately Strongly disagree
Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment	Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment Strongly agree	Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment Agree	Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment Neutral	Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment Disagree	Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment Strongly disagree
Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance	Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance Strongly agree	Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance Agree	Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance Neutral	Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance Disagree	Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance Strongly disagree

Question Title

* 18. Deborah Bade Horn, DO, MPH, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 19. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 20. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 21. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for Obesity or related disease states:

Question Title

* 1. Following your participation in this activity, how confident are you in the management of patients with obesity in your practice?

Question Title

Question Title

* 3. Which of the following areas are most heavily affected by obesity prevalence and why, according to a CDC analysis that divided the United States into 9 regional divisions?

Question Title

Question Title

* 5. Dr. Smith, a primary care physician, is considering using the AHA/ACC/TOS guideline algorithm with one of his patients who has a BMI of 27 with weight-related comorbidities. Would this this algorithm be an appropriate tool?

Question Title

* 6. Which patients should be considered for antiobesity medication? According to AACE guidelines, appropriate anti-obesity medication candidates are patients who have:

Question Title

* 7. Phase 3 preliminary trial results showing an average weight loss >18% after 68 weeks, were recently released for which agent now in clinical development?

Question Title

* 8. Which FDA-approved antiobesity medication or combination should be avoided in patients with seizure disorders, based on safety profile and contraindications?

Question Title

* 9. What is your degree?

Question Title

* 10. How many years have you been in practice?

Question Title

* 11. How many patients with obesity do you manage?

Question Title

* 12. Please select the option that best describes your practice setting:

Question Title

* 13. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 14. Which of the following best describes the impact of this activity on your performance?

Question Title

* 15. Which new strategies/skills/information will you incorporate into your practice? Please select all that apply.

Question Title

* 16. What barriers do you see to making changes in your practice?

Question Title

* 17. After participating in today’s activity, I am now better able to:

Question Title

* 18. Deborah Bade Horn, DO, MPH, effectively:

Question Title

* 19. The content presented:

Question Title

* 20. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 21. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for Obesity or related disease states:

Question Title

* 22. If you indicated that you perceived commercial bias or influence, please describe: